18 results with keyword: 'aberrant signaling pathways in cell acute lymphoblastic leukemia'
Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with
N/A
ERG+, aberrant ERG expression; AML, acute myeloid leukemia; T-ALL, T lymphoblastic leukemia; B-ALL, B lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; TMA,
N/A
T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous disease with respect to phenotype, gene expression profile and activation of particular
N/A
ALL: Acute lymphoblastic leukemia; T-ALL: T-cell acute lymphoblastic leukemia; B-ALL: B-cell acute lymphoblastic leukemia; MRD: Minimal residual disease; PR: Prednisone response;
N/A
we also observed co-occurrence of JAK2 and KRAS lesions in non-Down syndrome BCP-ALL cells. More importantly, these JAK2 and KRAS mutations showed different outgrowth
N/A
ALL: Acute lymphoblastic leukemia; AML: Acute myelocytic leukemia; BCP- ALL: B-cell precursor acute lymphoblastic leukemia; BLK: B lymphocyte kinase; BTK: Bruton ’ s tyrosine
N/A
Cell density Cell proliferation Cell viability (%) MCL-1 protein expression Bcl-2 protein expression Bim protein expression Normoxa More important Equal Equal Weakly expressed
N/A
T cell receptor delta gene recombinatorial events were found in 91% of acute T cell lymphoblastic leukemia, 68% of non-T, non-B lymphoid precursor acute.. lymphoblastic leukemia
N/A
Precursor T-cell lymphoblastic leukemia; T-cell acute lymphoblastic leukemia; T-cell ALL; T-ALL; T-cell receptor; thymocyte; transcription factor.. Clinics
N/A
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia
N/A
subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
N/A
Furthermore, the combination of nelarabine with ZSTK-474 was able to induce a decrease in the Bcl2 and Bcl-xL protein expression in all cell lines resistant to nelarabine alone,
N/A
leukemia; pre T-LBL, precursor T-cell lymphoblastic leukemia/lymphoma; AML, acute myeloid leukemia; DLBCL, diffuse large B-cell lymphoma; ALL, acute lymphocytic leukemia; T-ALL,
N/A
HSCT, hematopoietic stem-cell transplantation; Acute leukemia, acute myeloid leukemia (36%); acute lymphoblastic leukemia (24%); myelodysplastic syndrome (30%); other (10%);
N/A
Immunophenotypic characteristics of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients with ZNF384 -related fusion genes.. (A) Typical histograms of CD19, CD10,
N/A
ACAs: Additional cytogenetic abnormalities; ALL: Acute lymphoblastic leukemia; aMCB: Array-proven high-resolution multicolor banding; B-ALL: B cell acute lymphoblastic leukemia;
N/A
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ccRCC: Clear cell renal cell carcinoma; CML: Chronic myeloid leukemia; CNV: Copy number variant; CSC: Cancer stem
N/A